 HANOVER, March 17, 2021 GLOBE NEWSWIRE -- Processa Pharmaceuticals, Inc. Nasdaq: PCSA Processa or the Company, a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patients survival andor quality of life, today announces that it has selected 5 U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the Companys Phase 2B trial A Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica. Two to three additional clinical sites will be selected in the future including sites outside the U.S. 